222 related articles for article (PubMed ID: 16835747)
21. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Yamaki M; Sugiura K; Muro Y; Shimoyama Y; Tomita Y
Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Mio T; Mishima M
Oncol Rep; 2011 Oct; 26(4):795-803. PubMed ID: 21805046
[TBL] [Abstract][Full Text] [Related]
23. Expression of interleukin-2 receptor by activated peripheral blood lymphocytes upregulated by the plasma level of interleukin-2 in patients with recurrent aphthous ulcers.
Sun A; Chu CT; Liu BY; Wang JT; Leu JS; Chiang CP
Proc Natl Sci Counc Repub China B; 2000 Jul; 24(3):116-22. PubMed ID: 10943944
[TBL] [Abstract][Full Text] [Related]
24. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
25. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
Fang L; Sun X; Song Y; Zhang Y; Li F; Xu Y; Ma S; Lin N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):873-7. PubMed ID: 26310285
[TBL] [Abstract][Full Text] [Related]
26. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
27. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
28. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
29. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.
Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Okuda C; Mio T; Mishima M
Oncology; 2010; 79(5-6):355-62. PubMed ID: 21430404
[TBL] [Abstract][Full Text] [Related]
32. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
[TBL] [Abstract][Full Text] [Related]
33. CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy.
Barlési F; Tchouhadjian C; Doddoli C; Torre JP; Astoul P; Kleisbauer JP
Br J Cancer; 2005 Jan; 92(1):13-4. PubMed ID: 15597098
[TBL] [Abstract][Full Text] [Related]
34. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease.
Fägerstam JP; Whiss PA; Ström M; Andersson RG
Inflamm Res; 2000 Sep; 49(9):466-72. PubMed ID: 11071121
[TBL] [Abstract][Full Text] [Related]
35. The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients.
Kawashima O; Kamiyoshihara M; Sakata S; Endo K; Saito R; Morishita Y
Ann Surg Oncol; 2000 Apr; 7(3):239-45. PubMed ID: 10791856
[TBL] [Abstract][Full Text] [Related]
36. Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Li J; Hu YM; Du YJ; Zhu LR; Qian H; Wu Y; Shi WL
BMC Cancer; 2014 Nov; 14():848. PubMed ID: 25410981
[TBL] [Abstract][Full Text] [Related]
37. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Vasile E; Tibaldi C; Chella A; Falcone A
J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
[TBL] [Abstract][Full Text] [Related]
38. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.
Nishino K; Imamura F; Morita S; Mori M; Komuta K; Kijima T; Namba Y; Kumagai T; Yamamoto S; Tachibana I; Nakazawa Y; Uchida J; Minami S; Takahashi R; Yano Y; Okuyama T; Kumanogoh A
Lung Cancer; 2013 Nov; 82(2):299-304. PubMed ID: 24018023
[TBL] [Abstract][Full Text] [Related]
39. Changes in the levels of serum-soluble interleukin-2 receptor after surgical stress.
Murakami S; Sakata H; Tsuji Y; Okubo K; Takahashi T; Kikuchi M; Hirayama R
Surg Today; 2003; 33(8):565-70. PubMed ID: 12884092
[TBL] [Abstract][Full Text] [Related]
40. Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer.
Katoh R; Takenoshita S; Shimizu Y; Tanaka S; Yajima Y; Nagamachi Y
Anticancer Res; 1997; 17(5B):3787-92. PubMed ID: 9427781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
